Wealth Enhancement Advisory Services’s Lexicon Pharmaceuticals LXRX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.9K	Sell	12,139 -249	-2%	-$485	﹤0.01%	4005
2026 Q1	$19.7K	Sell	12,388 -1,132	-8%	-$1.65K	﹤0.01%	3504
2025 Q4	$15.4K	Sell	13,520 -5,357	-28%	-$7.36K	﹤0.01%	3603
2025 Q3	$28.7K	Sell	18,877 -55,577	-75%	-$63.1K	﹤0.01%	3482
2025 Q2	$67.1K	Buy	74,454 +5,247	+8%	+$3.4K	﹤0.01%	3194
2025 Q1	$31.9K	Buy	+69,207	New	+$43.7K	﹤0.01%	2880

Other funds holding LXRX

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Wealth Enhancement Advisory Services's LXRX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Lexicon Pharmaceuticals (LXRX) stake by 2% in Q2 2026, selling an estimated $485 and leaving 12,139 shares worth $26.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4005.

Wealth Enhancement Advisory Services first reported a position in LXRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $67.1K in Q2 2025. 4 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

Wealth Enhancement Advisory Services held 12,139 shares of Lexicon Pharmaceuticals worth $26.9K as of Q2 2026.
Wealth Enhancement Advisory Services sold 249 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $485.
Lexicon Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #4005 holding.
Wealth Enhancement Advisory Services first reported a position in Lexicon Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Wealth Enhancement Advisory Services's Lexicon Pharmaceuticals position peaked at $67.1K in Q2 2025.
4 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.